PAREXEL's Jeffery Fairbairn Discusses Key Issues at DIA 2014

June 19, 2014
One of the key issues that's being discussed at DIA this year is how sponsors can lower the overall costs of drug development and how CROs can help them do that. There are two ways that PAREXEL can really help to address this client need. The first is through our Partnership Value Model, which is a data driven tool that really helps clients think through the different levers that they can pull in order to lower the overall cost of drug development. The second is Study Optimization Services where we engage early with clients to help them write more efficient, more cost effective protocols. Through these offerings, we are providing some of the answers to sponsors on how they can lower the cost of drug development. We're not leaving this to sponsors to find themselves. This simplifies their journey.
Previous Video
PAREXEL Strategic Partnerships: Streamlining the Journey from Molecule to Market
PAREXEL Strategic Partnerships: Streamlining the Journey from Molecule to Market

This short video demonstrates how a Strategic Partnership with PAREXEL uses intelligent planning, streamlin...

Next Video
PAREXEL's Alberto Grignolo, PhD, Comments on Key Trends at DIA 2014
PAREXEL's Alberto Grignolo, PhD, Comments on Key Trends at DIA 2014

The major topics discussed at DIA today, at this particular annual meeting, I have found to be rather patie...